Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
Open Access
- 11 February 2013
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 11 (4), 670-678
- https://doi.org/10.1111/jth.12161
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8‐GP in haemophilia A dogsHaemophilia, 2012
- Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia AHaemophilia, 2011
- Prophylaxis in the haemophilia populationHaemophilia, 2010
- Purification and characterization of a new recombinant factor VIII (N8)Haemophilia, 2010
- Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' OrganisationHaemophilia, 2004
- Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspectiveHaemophilia, 2003
- Haemophilia prophylaxis in young patients–a long‐term follow‐upJournal of Internal Medicine, 1997
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992